JACOBIO-B (01167) released its interim results, with a profit attributable to shareholders of 601 million yuan, achieving a turnaround from losses to profits year-on-year.
Jacques-B (01167) announced its interim results for the six months ending June 30, 2026, reporting revenue of 731 million yuan, a year-on-year increase of 1500.5%; the profit attributable to shareholders was 601 million yuan, compared to a loss of 58.99 million yuan in the same period last year; basic earnings per share were 0.78 yuan.
JACOBIO-B (01167) announced its interim results for the six months ending June 30, 2026, reporting revenue of 731 million yuan, a year-on-year increase of 1500.5%; the profit attributable to shareholders was 601 million yuan, compared to a loss of 58.994 million yuan in the same period last year; basic earnings per share were 0.78 yuan.
The announcement noted that the revenue growth was mainly due to a strategic collaboration with AstraZeneca AB for the global R&D, production, and commercialization of JAB-23E73; and the establishment of licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the R&D, production, and commercialization of and sitneprotafib.
Related Articles
HUAYUEXPRESSWAY (01823) issues profit warning, expecting a mid-term shareholder loss of approximately 34.5 million to 38.1 million yuan.
IBM (IBM.US) has released the world's first dual-architecture mainframe processor that simultaneously supports both IBM and Arm (ARM.US) instruction sets.
Asymchem Laboratories (06821) announced its interim results, with a net profit attributable to shareholders of 520 million yuan, a year-on-year decrease of 15.71%.
HUAYUEXPRESSWAY (01823) issues profit warning, expecting a mid-term shareholder loss of approximately 34.5 million to 38.1 million yuan.
IBM (IBM.US) has released the world's first dual-architecture mainframe processor that simultaneously supports both IBM and Arm (ARM.US) instruction sets.
Asymchem Laboratories (06821) announced its interim results, with a net profit attributable to shareholders of 520 million yuan, a year-on-year decrease of 15.71%.
RECOMMEND
